国际共识关于肉毒毒素 A （Speywood 单位）美学应用的推荐意见——第一部分：上面部皱纹。

International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.

机构信息

Clinique de Chirurgie Esthétique Iéna, Paris, France.

出版信息

J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1278-84. doi: 10.1111/j.1468-3083.2010.03631.x.

DOI:10.1111/j.1468-3083.2010.03631.x

PMID:20337830

Abstract

BACKGROUND

Azzalure (Galderma SA) is a newly approved European botulinum neurotoxin type A (BoNT-A). It is derived from Dysport (Ipsen Pharma), which has a long history of usages in various applications. Azzalure and Dysport are collectively referred to as BoNT-A (Speywood Unit) and are different from other BoNT-A preparations.

OBJECTIVE

To provide consensus recommendations on the treatment of upper face wrinkles with BoNT-A (Speywood Unit).

METHODS

The members of the International Board on Botulinum toxin Azzalure (IBBA) convened to develop consensus on the treatment of upper facial wrinkles based on their own extensive experience.

RESULTS

The consensus recommendations address the general issues regarding treatment and provide specific guidelines on the anatomy, injection points, dose, injection technique and safety precautions concerning each common upper face indication. The recommended final concentration of BoNT-A (Speywood Unit) is 200 s.U/mL (10 s.U/0.05 mL) after reconstitution. For glabellar lines, the members recommend a total of five injection points with 10 s.U/point. For forehead wrinkles, the members recommend four to six injections into the frontalis with 5-10 s.U/point. For crow's feet, the members recommend three injections per side with 5-10 s.U/point at the lateral part of the orbicularis oculi. For lateral eyebrow lift, the members recommend one point at each eyebrow tail and an additional one in each side of the frontalis with 5-10 s.U/point.

CONCLUSION

This guideline provides a framework for physicians who wish to perform safe and efficacious injection of BoNT-A (Speywood Unit).

摘要

背景

Azzalure（高德美公司）是一种新获得批准的欧洲型 A 肉毒毒素（BoNT-A）。它源自 Dysport（益普生制药公司），后者在各种应用中已有长期使用历史。Azzalure 和 Dysport 统称 BoNT-A（Speywood 单位），与其他 BoNT-A 制剂不同。

目的

为 BoNT-A（Speywood 单位）治疗上面部皱纹提供共识建议。

方法

国际 Azzalure 肉毒毒素委员会（IBBA）成员根据自身的丰富经验开会，就上面部皱纹的治疗达成共识建议。

结果

共识建议涉及治疗的一般问题，并就每个常见上面部适应证的解剖结构、注射点、剂量、注射技术和安全注意事项提供具体指南。推荐的 BoNT-A（Speywood 单位）最终浓度为复溶后 200 s.U/mL（10 s.U/0.05 mL）。对于眉间纹，成员建议总共 5 个注射点，每个点注射 10 s.U。对于额纹，成员建议在额肌中注射 4-6 个点，每个点 5-10 s.U。对于鱼尾纹，成员建议每侧注射 3 个点，外眦眼轮匝肌外侧注射 5-10 s.U。对于外侧眉提升，成员建议在每个眉尾和额肌两侧各注射 1 点，每个点注射 5-10 s.U。